BioCentury | Nov 23, 2015
Clinical News

Narcan naloxone regulatory update

...from the scientific literature or from previously approved products. Adapt Pharma Ltd. , Dublin, Ireland Lightlake Therapeutics Inc....
BioCentury | Oct 19, 2015
Clinical News

Narcan naloxone regulatory update

...and commercialize the opioid antagonist nasal spray from Lightlake. Adapt Pharma Ltd. , Dublin, Ireland Lightlake Therapeutics Inc....
BioCentury | Aug 3, 2015
Clinical News

Narcan intranasal naloxone regulatory update

...rights to develop and commercialize the product from Lightlake. Adapt Pharma Ltd. , Dublin, Ireland Lightlake Therapeutics Inc....
BioCentury | Nov 3, 2014
Company News

Lightlake Therapeutics deal

...Phase I trial, and the binge eating disorder product has completed a Phase II trial. Lightlake Therapeutics Inc....
BioCentury | Aug 4, 2014
Financial News

Lightlake Therapeutics financial update

Lightlake Therapeutics Inc. (OTCBB:LLTP), London, U.K. Business: Neurology Date announced: 2014-07-30 Note: Lightlake received a funding commitment for up to $3 million from an undisclosed R&D foundation. If the entire $3 million is invested, the...
BioCentury | Sep 30, 2013
Clinical News

Intranasal naloxone: Phase I started

...disorder. Lightlake plans to begin a Phase II trial in bulimia nervosa in late 2014. Lightlake Therapeutics Inc....
BioCentury | Dec 10, 2012
Company News

Lightlake Therapeutics management update

Lightlake Therapeutics Inc. (OTCBB:LLTP), London, U.K. Business: Neurology Hired: Kevin Pollack, a director, as CFO WIR Staff Neurology...
BioCentury | Oct 1, 2012
Company News

Lightlake Therapeutics management update

Lightlake Therapeutics Inc. (OTCBB:LLTP), London, U.K. Business: Neurology Appointed: David Kessler, former U.S. FDA commissioner, as a strategic advisor WIR Staff...
BioCentury | May 21, 2012
Clinical News

Intranasal naloxone: Preliminary Phase II data

...to start a Phase II trial of the product to treat bulimia nervosa this year. Lightlake Therapeutics Inc....
BioCentury | Jan 9, 2012
Company News

Lightlake Therapeutics, King's College London deal

...at the university to treat bulimia. Details were not disclosed (see BioCentury, Aug. 29, 2011). Lightlake Therapeutics Inc....
Items per page:
1 - 10 of 11
BioCentury | Nov 23, 2015
Clinical News

Narcan naloxone regulatory update

...from the scientific literature or from previously approved products. Adapt Pharma Ltd. , Dublin, Ireland Lightlake Therapeutics Inc....
BioCentury | Oct 19, 2015
Clinical News

Narcan naloxone regulatory update

...and commercialize the opioid antagonist nasal spray from Lightlake. Adapt Pharma Ltd. , Dublin, Ireland Lightlake Therapeutics Inc....
BioCentury | Aug 3, 2015
Clinical News

Narcan intranasal naloxone regulatory update

...rights to develop and commercialize the product from Lightlake. Adapt Pharma Ltd. , Dublin, Ireland Lightlake Therapeutics Inc....
BioCentury | Nov 3, 2014
Company News

Lightlake Therapeutics deal

...Phase I trial, and the binge eating disorder product has completed a Phase II trial. Lightlake Therapeutics Inc....
BioCentury | Aug 4, 2014
Financial News

Lightlake Therapeutics financial update

Lightlake Therapeutics Inc. (OTCBB:LLTP), London, U.K. Business: Neurology Date announced: 2014-07-30 Note: Lightlake received a funding commitment for up to $3 million from an undisclosed R&D foundation. If the entire $3 million is invested, the...
BioCentury | Sep 30, 2013
Clinical News

Intranasal naloxone: Phase I started

...disorder. Lightlake plans to begin a Phase II trial in bulimia nervosa in late 2014. Lightlake Therapeutics Inc....
BioCentury | Dec 10, 2012
Company News

Lightlake Therapeutics management update

Lightlake Therapeutics Inc. (OTCBB:LLTP), London, U.K. Business: Neurology Hired: Kevin Pollack, a director, as CFO WIR Staff Neurology...
BioCentury | Oct 1, 2012
Company News

Lightlake Therapeutics management update

Lightlake Therapeutics Inc. (OTCBB:LLTP), London, U.K. Business: Neurology Appointed: David Kessler, former U.S. FDA commissioner, as a strategic advisor WIR Staff...
BioCentury | May 21, 2012
Clinical News

Intranasal naloxone: Preliminary Phase II data

...to start a Phase II trial of the product to treat bulimia nervosa this year. Lightlake Therapeutics Inc....
BioCentury | Jan 9, 2012
Company News

Lightlake Therapeutics, King's College London deal

...at the university to treat bulimia. Details were not disclosed (see BioCentury, Aug. 29, 2011). Lightlake Therapeutics Inc....
Items per page:
1 - 10 of 11